ALBERTA BLUE CROSS®

ADALIMUMAB / GOLIMUMAB / INFLIXIMAB / VEDOLIZUMAB for Ulcerative Colitis SPECIAL AUTHORIZATION REQUEST FORM

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

Please complete all required sections to allow your request to be processed.

PATIENT INFORMATION

PATIENT LAST NAME	FIRST NAME	INITIAL

BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER

STREET ADDRESS	CITY	PROV	POSTAL CODE

COVERAGE TYPE

- ☐ Alberta Blue Cross
- ☐ Alberta Human Services
- ☐ Other

ID, CLIENT OR COVERAGE NUMBER

PRESCRIBER INFORMATION

PRESCRIBER LAST NAME	FIRST NAME	INITIAL

STREET ADDRESS

CITY, PROVINCE

POSTAL CODE

PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION

- ☐ CPSA
- ☐ CARNA
- ☐ ACP
- ☐ ACO
- ☐ ADA+C
- ☐ Other

REGISTRATION NUMBER

PHONE

FAX

FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED

Please provide the following information for ALL requests

Diagnosis

- ☐ Ulcerative Colitis
- ☐ Other (please specify)

_____

Indicate requested drug

- ☐ Entyvio
- ☐ Humira
- ☐ [1]Inflectra
- ☐ [1]Remicade
- ☐ [1]Renflexis
- ☐ Simponi

1. See p. 2 for Biosimilar Switch Policy

Current weight (kg)

Dosage and frequency

Date of last dose

For patients new to coverage but currently maintained on the requested drug, please provide the treatment start date (YYYY-MM-DD) _____

Please provide reason if a switch to a different biologic agent or change in dose is requested

Note patients will not be permitted to switch back to a previously trialed biologic agent if they were deemed unresponsive to therapy.

***Pre-treatment score**

Partial Mayo score _____ Date _____

Current score

Partial Mayo score _____ Date _____

*Requests for patients new to the requested drug and requests for patients new to coverage but currently m aintained on the requested drug require pre-treatment scores. The Partial Mayo Score is a 9 point score consisting of 3 domains (same as full mayo except endoscopic findings are eliminated). Please provide exact score(s).

For INITIAL requests - dose, duration and response are required for all medications previously utilized. If the following medications were not tried, please provide reason.

- ☐ Mesalamine
- ☐ Corticosteroids (please specify drug name)
- ☐ Other (please specify)

For requests to increase maintenance dosing to Infliximab 10 mg/kg or Golimumab 100 mg

1) Is the patient already maintained on a dose of infliximab 10 mg/kg or golimumab 100 mg? ☐ Yes ☐ No

2) Has the patient had a *secondary loss of response* while on maintenance dosing with Infliximab 5 mg/kg or Golimumab 50 mg?

☐ Yes ☐ No (explain) _____

3) Provide the most recent partial Mayo score from when the patient was *responding* to maintenance dosing with Infliximab 5 mg/kg or Golimumab 50 mg _____ Date of Score _____

Additional information relating to request

PRESCRIBER'S SIGNATURE	DATE

Please forward this request to
Alberta Blue Cross, Clinical Drug Services
10009 108 Street NW, Edmonton, Alberta, T5J 3C5
FAX 780-498-8384 in Edmonton • **1-877-828-4106** toll free all other areas

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 108 Street, Edmonton AB, T5J 3C5.

ALBERTA BLUE CROSS®

ADALIMUMAB / GOLIMUMAB / INFLIXIMAB / VEDOLIZUMAB for Ulcerative Colitis SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government sponsored drug programs.

1. Biosimilar Switch Policy

As of December 12, 2019, adult (18 years of age and older) patients using an originator biologic for which there is a biosimilar treatment option for their indication and who wish to maintain Alberta Health coverage of the molecule will be required to switch to the biosimilar by January 15, 2021. During the transition period from December 12, 2019 to January 14, 2021, Alberta Health will cover both the originator biologic and the biosimilar(s) of the affected drug(s). Effective January 15, 2021, Alberta Health will only cover the biosimilar versions of the drugs listed below, for the affected indications.

Drug	Originator (Switch from)	Biosimilar (Switch to)	Indication
Infliximab	Remicade	Inflectra or Renflexis	Ulcerative Colitis

For Biosimilar Initiative Exception Requests

Please complete the Biosimilar Initiative / Tiering Exception Special Authorization Request Form.

\